Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR)
This study is currently recruiting participants.
Verified July 2017 by INC Research
Hetero Labs Ltd.
Janssen Scientific Affairs
Lupin Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Prinston Pharmaceutical Inc.
Ranbaxy Inc., a SunPharma Co.
Sciegen Pharmaceuticals Inc.
Silarx Pharmaceuticals Inc
Strides Shasun Ltd.
Teva Pharmaceuticals USA
Amneal Pharmaceuticals, LLC
Dr. Reddy's Laboratories UK Ltd.
Information provided by (Responsible Party):
First received: November 27, 2006
Last updated: July 3, 2017
Last verified: July 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||January 2099|
|Estimated Primary Completion Date:||January 2099 (Final data collection date for primary outcome measure)|